Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07687511
Starting soon Not applicable

Oral Microbiota and Muscle Function in the Ageing Subject

NCT07687511 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Rouen
Phase
Not applicable
Started
2026-07
Last updated
2026-07-07

Condition(s) studied

Non-hospitalised Men and Women Over 70 Years of Age

Investigational drug(s) / intervention(s)

Salivary and fecal microbiota sampling and muscle strength assessment

Salivary and fecal microbiota sampling and muscle strength assessment: Collection of saliva and stool samples for microbiota analysis and assessment of handgrip strength in adults aged over 70 years.

Study summary

Ageing of the general population may be a risk factor for various complications, including sarcopenia. Sarcopenia is a progressive loss of muscle mass and muscle strength, leading to a decrease in functional capacities. It affects between 0.7% and 16% of European adults over 70 years of age (1). Recent studies suggest that the faecal microbiota may be altered with ageing but also according to sarcopenic status. Furthermore, no study has currently published data on the relationship between salivary microbiota and sarcopenic status. The main hypothesis of this study is that a decrease in salivary microbiota richness could be associated with impaired handgrip strength in the ageing subject.

Eligibility

Sex
ALL
Min age
70 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female adult volunteer, over 70 years of age * Non-hospitalised * Having read and understood the information letter and signed the consent form * Affiliated with a Social Security scheme Exclusion Criteria: * Already included in an interventional drug clinical trial * Unable to understand and complete the questionnaires * Deprived of liberty by an administrative or judicial decision or protected adult subject (under guardianship, curatorship or judicial protection order) * Receiving antibiotic treatment or having received antibiotic treatment during the previous 3 months * Taking or having taken probiotics during the previous 3 months * Having undergone colonic lavage/bowel cleansing during the previous 3 months * Presenting one of the following situations likely to alter the microbiota: active cancer, eating disorders, exclusive vegetarian diet, history of digestive surgery * Having a cardiac pacemaker * Living in a nursing home for dependent elderly persons (EHPAD)

Primary outcome measure(s)

  • Salivary microbiota richness — baseline
    Salivary microbiota richness (gene richness/alpha diversity) measured from saliva samples.

Trial sites (1)

FacilityCityRegionStatus
Rouen University Hospital Rouen France

More University Hospital, Rouen trials in France

Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Active, not recruiting
Non-invasive Ventilation and High-speed Oxygen Therapy Effects on Heart Function - HiFlow-Heart Study Recruiting
NUTritional Impact of a Hypocaloric Hyperprotein Diet Before Obesity Surgery Recruiting
Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome Recruiting
Mechanisms of Action on Rectal Motricity of Intrarectal Botulinum Toxin Injections Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07687511 on ClinicalTrials.gov ↗ ← All trials in France